This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
7 Dec 2015

Aptar Pharma presents a step change in the performance of DF30Plus for pMDIs incorporating COC

The new version of DF30Plus, which incorporates a neck gasket manufactured with COCe, offers several key benefits.

Aptar Pharma will present its latest innovation, DF30Plus with COCe, at the Drug Delivery to the Lungs (DDL) scientific conference in Edinburgh, Scotland, 9–11 December 2015.

Each year, several hundred million metering valves are produced in Aptar Pharma’s three manufacturing facilities strategically located across Europe and Asia. Aptar Pharma is the only metering valve supplier that designs, develops and manufactures its own elastomer gaskets — a key component of the valve — within its unique in-house Elastomer Center.

DF30Plus with COCe: ultra-clean, robust and versatile

Aptar Pharma’s DF30 metering valve technology platform has been the industry gold standard for more than 20 years and the company are constantly striving to optimize its DF30 product offering.

COC is a well-known and characterized material used for injectable drug containers. COCe is a specific version of COC that has unique elastomeric properties while being ultraclean and inert.


The new version of DF30Plus that incorporates a neck gasket manufactured with COCe offers several key benefits:
  • Step change improvement as a barrier to leakage
  • Ultra low extractible level
  • Compatibility across a wider range of drug formulations, including ethanol-containing formulations
  • Suitable for all pMDI filling technologies
  • Robust design for accurate and consistent performance


  • “Thanks to the introduction of our novel COCe within our DF30 Valve Technology Platform, Aptar Pharma is able to offer a series of key advantages to meet the evolving needs of our customers; including improved compatibility with both EtOH containing and dry drug formulations, superior cleanliness and improved leakage barrier characteristics which result in a more robust and less crimp sensitive manufacturing process,” said Chris Baron, Associate Director, Business Development, for Aptar Pharma.

    Related News